Display options
Cite
Johnson TL, Topol EJ. Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. J Thromb Thrombolysis. 1997;4(2):259-266doi: 10.1023/a:1008899002382.
Johnson, T. L., & Topol, E. J. (1997). Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. Journal of thrombosis and thrombolysis, 4(2), 259-266. https://doi.org/10.1023/a:1008899002382
Johnson, and Topol. "Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion." Journal of thrombosis and thrombolysis vol. 4,2 (1997): 259-266. doi: https://doi.org/10.1023/a:1008899002382
Johnson TL, Topol EJ. Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. J Thromb Thrombolysis. 1997;4(2):259-266. doi: 10.1023/a:1008899002382. PMID: 10639267.
Copy Download .nbib Format: NLM
Share it on

J Thromb Thrombolysis. 1997;4(2):259-266. doi: 10.1023/a:1008899002382.

Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Journal of thrombosis and thrombolysis

Johnson, Topol

Affiliations

  1. Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

PMID: 10639267 DOI: 10.1023/a:1008899002382

Abstract

Early clinical trials of thrombolytic therapy in the setting of acute myocardial infarction (AMI) demonstrated that early angiographic reperfusion correlated with improved survival. This supported the open-artery hypothesis that early reperfusion decreases infarct size, improves left ventricular function, and improves survival. Two subsequent comparative thrombolytic trials showed no difference in left ventricular function or survival between agents with different rates of reperfusion. Additionally, reduction in mortality was demonstrated without improvement in left ventricular function and with the late administration of thrombolytic therapy. Therefore, there was a real question as to the importance of infarct vessel patency, and its relation to clinical outcome. This article discusses the various markers of coronary artery patency, their relation to clinical outcome, and how they reflect perfusion at the tissue level. The coronary angiogram gives a snapshot view of the infarct-related artery (IRA) that does not reflect the dynamic process of vessel reocclusion and recanalization. The patent artery is therefore "open" at only a given time frame, and may undergo cyclic or complete reocclusion. Angiographically characterized flow has been demonstrated to be more clinically meaningful. The GUSTO-I trial was designed to test the open-artery hypothesis. This trial confirmed that improved early IRA patency and optimal (TIMI-3) flow correlated with improved survival. The presence of TIMI-3 flow in the IRA has consistently demonstrated significant improvement in patient morbidity and mortality, and conversely, less than optimal, but still "patent" (TIMI-2) flow in the IRA correlates with clinical outcomes observed in patients with occluded infarct vessels. Even TIMI-3 flow in the IRA does not always confirm perfusion of the myocardium at risk. Therefore, the "patent" IRA can be subsequently compromised by intermittent patency, reocclusion, less than TIMI-3 flow, and a "no-reflow" effect at the tissue level. The development of accurate, reliable non-invasive markers of IRA patency is crucial. This would allow a more selective application of invasive and interventional techniques to restore patency to the IRA. The merits and faults of these noninvasive markers are discussed. The ideal gold standard for establishing the adequacy of therapy in AMI is one that could detect rapid, complete, and sustained coronary reperfusion with adequate myocardial perfusion. Current technologic achievements allow an approach to this ideal; however, as of 1997, the coronary angiogram demonstrating TIMI-3 flow represents the clinically proven standard of optimal therapeutic efficacy.

References

  1. J Am Coll Cardiol. 1993 May;21(6):1391-5 - PubMed
  2. J Clin Invest. 1974 Dec;54(6):1496-508 - PubMed
  3. J Am Coll Cardiol. 1991 Jul;18(1):44-9 - PubMed
  4. Lancet. 1990 Jul 14;336(8707):65-71 - PubMed
  5. N Engl J Med. 1987 Sep 3;317(10):581-8 - PubMed
  6. Am J Cardiol. 1993 May 20;71(14 ):34D-40D - PubMed
  7. Am J Cardiol. 1993 May 20;71(14 ):3D-9D - PubMed
  8. Circulation. 1987 Jul;76(1):142-54 - PubMed
  9. N Engl J Med. 1986 Jun 5;314(23 ):1465-71 - PubMed
  10. N Engl J Med. 1987 Oct 22;317(17):1055-9 - PubMed
  11. Am Heart J. 1991 Oct;122(4 Pt 1):943-8 - PubMed
  12. J Am Coll Cardiol. 1988 Jan;11(1):59-65 - PubMed
  13. Circulation. 1987 Jul;76(1):44-51 - PubMed
  14. Am Heart J. 1993 Aug;126(2):279-85 - PubMed
  15. Int J Cardiol. 1989 Feb;22(2):161-8 - PubMed
  16. N Engl J Med. 1984 Dec 6;311(23):1488-92 - PubMed
  17. N Engl J Med. 1993 Mar 11;328(10 ):673-9 - PubMed
  18. J Am Coll Cardiol. 1994 Aug;24(2):370-7 - PubMed
  19. J Am Coll Cardiol. 1992 Dec;20(7):1452-9 - PubMed
  20. N Engl J Med. 1985 Apr 25;312(17):1073-8 - PubMed
  21. N Engl J Med. 1985 Apr 4;312(14 ):932-6 - PubMed
  22. Circulation. 1990 Sep;82(3):781-91 - PubMed
  23. Circulation. 1987 Aug;76(2 Pt 2):II57-62 - PubMed
  24. J Am Coll Cardiol. 1994 May;23(6):1382-9 - PubMed
  25. Br Heart J. 1990 Aug;64(2):113-7 - PubMed
  26. J Am Coll Cardiol. 1993 May;21(6):1319-27 - PubMed
  27. J Am Coll Cardiol. 1992 Jul;20(1):17-23 - PubMed
  28. N Engl J Med. 1980 Oct 16;303(16):897-902 - PubMed
  29. Circulation. 1993 Jun;87(6):1829-39 - PubMed
  30. J Am Coll Cardiol. 1993 Jan;21(1):55-61 - PubMed
  31. J Am Soc Echocardiogr. 1994 Jul-Aug;7(4):337-46 - PubMed
  32. Am J Cardiol. 1985 Apr 1;55(8):889-95 - PubMed
  33. Eur Heart J. 1991 Jan;12 (1):34-8 - PubMed
  34. Circulation. 1991 Jan;83(1):126-40 - PubMed
  35. Circ Res. 1966 Jul;19(1):57-62 - PubMed
  36. Lab Invest. 1979 Jun;40(6):633-44 - PubMed
  37. Circulation. 1989 Feb;79(2):441-4 - PubMed
  38. Circulation. 1988 Mar;77(3):678-84 - PubMed
  39. Am J Cardiol. 1989 Mar 15;63(11):641-6 - PubMed
  40. Am J Cardiol. 1987 Mar 1;59(6):513-5 - PubMed
  41. Circulation. 1992 May;85(5):1699-705 - PubMed
  42. J Am Coll Cardiol. 1988 Apr;11(4):729-34 - PubMed
  43. Am J Cardiol. 1988 Sep 15;62(9):538-42 - PubMed
  44. Magn Reson Med. 1993 Oct;30(4):447-57 - PubMed
  45. Circulation. 1980 Nov;62(5):945-52 - PubMed
  46. N Engl J Med. 1983 Dec 15;309(24):1477-82 - PubMed
  47. J Am Coll Cardiol. 1992 Aug;20(2):307-13 - PubMed
  48. Circulation. 1981 Feb;63(2):307-17 - PubMed
  49. Am J Cardiol. 1988 Aug 1;62(4):179-85 - PubMed
  50. Circulation. 1995 Apr 1;91(7):1923-8 - PubMed
  51. Br Heart J. 1985 Jul;54(1):6-10 - PubMed
  52. Lancet. 1992 Mar 28;339(8796):753-70 - PubMed
  53. J Am Coll Cardiol. 1992 Jan;19(1):1-10 - PubMed
  54. Circulation. 1993 Aug;88(2):437-46 - PubMed
  55. Am Heart J. 1992 Mar;123(3):782-4 - PubMed
  56. J Clin Invest. 1989 Jul;84(1):18-27 - PubMed
  57. Lancet. 1988 Aug 13;2(8607):349-60 - PubMed
  58. N Engl J Med. 1989 Mar 30;320(13):817-21 - PubMed
  59. Am Heart J. 1994 Sep;128(3):426-34 - PubMed
  60. Am J Cardiol. 1991 Jan 15;67(2):109-15 - PubMed
  61. Am Heart J. 1988 Jan;115(1 Pt 1):1-7 - PubMed
  62. Circulation. 1995 May 15;91(10 ):2627-34 - PubMed
  63. Circulation. 1994 Sep;90(3):1492-501 - PubMed
  64. Circulation. 1993 Sep;88(3):1361-74 - PubMed
  65. Am J Cardiol. 1993 Feb 15;71(5):428-30 - PubMed
  66. Circulation. 1991 Mar;83(3):902-12 - PubMed
  67. J Am Coll Cardiol. 1991 Apr;17(5):1047-52 - PubMed

Publication Types